Enrollment for multiple arms in Stata PATH is based on novel algorithms Strata Oncology developed using its clinical molecular database comprising DNA mutation profiles and quantitative RNA expression data, as well as detailed treatment history and outcome data, from tens of thousands of patients.
All therapies being evaluated in Strata PATH are FDA-approved in oncology with demonstrated safety profiles in the advanced setting. Strata PATH will enroll patients with advanced cancer, as well as patients with early-stage cancer who have evidence of micrometastatic disease after initial treatment.
Strata oncology trial#
The Strata Precision Indications for Approved THerapies (Strata PATH) trial, is a 700-patient prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. Patients interested in learning more about the Strata PATH trial can visit and search for the Strata PATH Trial identifier: NCT05097599.
"We look forward to leveraging our cutting-edge patient identification strategies to expand access to the latest therapies through the Strata PATH clinical trial." "The Strata PATH study aligns with our mission to advance cancer therapies and offer personalized cancer care close to home," said Andrew McKenzie, Vice President, Personalized Medicine, Sarah Cannon Research Institute. Partnering with leading organizations like SCRI is integral to expanding the reach of this transformative clinical trial." "In the Strata PATH trial, we are investigating how our innovative molecular profiling platform and our novel quantitative RNA algorithms can be used to optimize and expand the use of cancer treatments across therapeutic classes. "Strata is thrilled to partner with SCRI to bring new advances and increased options to patients with both late-stage and early-stage cancer," said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. A range of therapeutic classes will be evaluated across tumor types, including targeted therapies, antibody-drug conjugates, immunotherapies, and angiogenesis inhibitors. Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations.
Researchers will enroll patients at eight SCRI-affiliated sites including: 16, 2022 /PRNewswire/ - Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that Sarah Cannon Research Institute (SCRI) has joined the Strata P recision Indications for A pproved TH erapies (Strata PATH ™) trial. Trial will evaluate FDA-approved cancer therapies in new, biomarker-guided patient populationsĪNN ARBOR, Mich., Aug.
0 kommentar(er)
